Novavax names John Jacobs as new CEO, succeeding Stanley Erck

Novavax (NVAX) announced that John Jacobs will succeed Stanley Erck as President and CEO and a member of the Board of Directors. The transition will be effective as of January 23. Erck will serve as an advisor to the company for the next fifteen months to enable a smooth transition. Jacobs brings more than 25 years of commercial, operations, business and leadership experience across multiple therapeutic areas. He will join Novavax from Harmony Biosciences (HRMY), where he has served as President and CEO and a member of the Board of Directors since June 2018, and Executive Vice President and Chief Commercial Officer from October 2017 to June 2018.